Use of anti-rheumatic drugs during pregnancy;O uso de drogas anti-reumáticas na gravidez

Revista Brasileira de Reumatologia

Volumn 45, Issue 3, 2005, Pages 124-133

  Levy, Roger A ^a,b  

^a FCM UERJ   (Brazil)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

Hydroxychloroquine; NSAIDs; Prednisone; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CYCLOBENZAPRINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; SERTRALINE; TERATOGENIC AGENT; UNINDEXED DRUG; WARFARIN;

BLEEDING; CONCEPTION; CONGENITAL HEART BLOCK; DRUG EFFECT; DRUG USE; FERTILE PERIOD; FETUS CIRCULATION; FETUS RISK; FOOD AND DRUG ADMINISTRATION; GESTATION PERIOD; HUMAN; KIDNEY MALFORMATION; LACTATION; LOW DRUG DOSE; NEONATAL HEMORRHAGE; NIDATION; NONHUMAN; PREGNANCY; PREGNANCY COMPLICATION; PRESCRIPTION; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 33645450063     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Briggs GG, Freeman RK, Yaffe SJ: Drugs in pregnancy and lactation. 6th ed, Lippincott Williams and Wilkins, Philadelphia, PA, 2002.
2. Gordon C: Pregnancy and autoimmune diseases. Best Pract Res Clin Rheumatol 18: 359-67, 2004.
3. Østensen M: Disease specific problems related to drug therapy in pregnancy. Lupus 13: 746-50, 2004.
4. Janssen NM, Genta MS: The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 160: 610-9, 2000.
5. Thulstrup AM, Sorensen HT, Nielsen GL, et al: Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. Euro Map Study Group Am J Perinatol 16: 321-6, 1999.
6. [No authors listed]: Committee on Drugs American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 93: 137-150, 1994.
7. Tincani A, Branch DW, Levy RA, et al: Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12: 524-9, 2003.
8. Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT: Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15: 483-6, 2001.
9. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99: 2385-92, 2004.
10. Kimby E, Sverrisdottir A, Blinder G: Safety of rituximab therapy during the first trimester of pregnancy: A case history. Eur J Haematol 72: 292-5, 2004.
11. Khanna D, McMahon M, Furst DE: Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27: 307-24, 2004.
12. Sills ES, Perloe M, Tucker MJ, Kaplan CR, Palermo GD: Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion aiiti-cytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 46: 366-8, 2001.
13. Parilla BV, Grobman WA, Holtzman RB, Thomas HA, Dooley SL: Indomethacin tocolysis and risk of necrotizing enterocolitis. Obstet Gynecol 96: 120-3, 2000.
14. Nielsen GL, Sorensen HT, Larsen H, Pedersen L: Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J 322: 266-70, 2001.
15. Li DK, Liu L, Odouli R: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br Med J 327(7411): 368, 2003.
16. Østensen M, Østensen H: Safety of nonsteroidal antiinflammatory drugs in pregnant pacientes with rheumatic disease. J Rheumatol 23: 1045-9, 1996.
17. Sookvanichsilp N, Pulbutr P. Anti-implantation effects of indomethacin and celecoxib in rats. Contraception 65: 373-8, 2002.
18. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A: Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 18: 93-101, 2004.
19. Jobe AH, Soll RF: Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 190: 878-81, 2004.
20. Rayburn WF: Connective tissue disorders and pregnancy. Recommendations for prescribing. J Reprod Med 43: 341-9, 1998.
21. Parke AL, Rothfield NF: Antimalarial drugs in pregnancy - the North American experience. Lupus 5 Suppl 1: S67-9, 1996.
22. Borden MB, Parke AL: Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf 24: 1055-63, 2001.
23. Klinger G, Morad Y, Westall CA, et al: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358(9284): 813-4, 2001.
24. Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M: Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology 41: 643-50, 2002.
25. Levy RA, Vilela VS, Cataldo MJ, et al: Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10: 401-4, 2001.
26. Al-Herz A, Schulzer M, Esdaile JM. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 29: 700-6, 2002.
27. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48: 3207-11, 2003.
28. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F: Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations Obstet Gynecol 103: 1091-4, 2004.
29. Pergola PE, Kancharla A, Riley DJ: Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 71: 994-7, 2001.
30. Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 36: 51-6, 2003.
31. Moskovitz DN, Bodian C, Chapman ML, et al: The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99: 656-61, 2004.
32. Rajapakse R, Korelitz BI: Inflammatory Bowel Disease During pregnancy. Curr Treat Options Gastroenterol 4: 245-251, 2001.
33. Cimaz R, Meregalli E, Biggioggero M, et al. Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicol Lett 149: 155-62, 2004.
34. Lyle WH: Penicillamine in pregnancy. Lancet 1: 606-7, 1998.
35. Matalon ST, Ornoy A, Lishner M: Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 18: 219-30, 2004.
36. Loyd ME, Carr M, Mcelhatton P, Hall GM, Hughes RA: The effect of methotrexate on pregnancy, fertility and lactation. QJ Med 92: 551-63, 1999.
37. Chakravarty EF, Sanchez-Yamamoto D, Bush TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 30: 241-6, 2003.
38. Østensen M, Khamashta MH, Lockshin MD, et al: Antirheumatic drug therapy and reproduction. Arthritis Rheum, submetido para publicaçã o, 2005.